BMRNBioMarin Pharmaceutical

Median target
$88
calls from the last 12 months
Implied return
+35.2%
median target vs. price
Coverage
27 analysts · 32 calls
updated in the last 12 months
Consensus
21/6/0+21 net
Buy / Hold / Sell

Which analysts are behind BMRN's consensus?

See every current rating, price target and the analysts' track records for BioMarin Pharmaceutical — plus the full analyst rankings, firm analytics and screener.

The consensus above reflects 27 analysts with calls on BMRN updated in the last 12 months. Implied return is the move implied if the consensus target were hit. These are forward-looking predictions, not realized returns. Per-analyst ratings and track records are a Premium feature.

BMRN elsewhere on AnalystEdge

The most recent congressional, executive-branch and insider filings matched to this ticker. Matched by ticker symbol — occasional mismatches are possible. Not investment advice.

Trending today: not in any of today's trending tables (Gaining attention, Losing attention, Most followed)

DateSourceWhoActionDetailAmount
2026-09-02InsidersDavis George EricEVP, Chief Legal OfficerInsider sale17.6K sh @ $66.28$1.2M
2025-09-08ExecutiveTrump, Donald JPresidentSaleBiomarin Pharmaceutical Inc$1,001 - $150,009
2025-08-07ExecutiveTrump, Donald JPresidentSaleBiomarin Pharmaceutical Inc$1,001 - $15,000
2025-08-04ExecutiveTrump, Donald JPresidentPurchaseBiomarin Pharmaceutical Inc$1,001 - $150,008
2025-06-12ExecutiveTrump, Donald JPresidentSaleBiomarin Pharmaceutical Inc$1,001 - $150,006
2025-04-11ExecutiveTrump, Donald JPresidentPurchaseBiomarin Pharmaceutical Inc$1,001 - $150,004
2025-01-06ExecutiveTrump, Donald JPresidentPurchaseBiomarin Pharmaceutical Inc$1,001 - $150,001
2020-12-30CongressGilbert CisnerosCA-CA39Purchasesince trade -26.5%, vs market -146.4%$15K–$50K
2019-12-16CongressJosh GottheimerNJ-NJ05Purchasesince trade -23.4%, vs market -185.6%$1K–$15K
2019-12-11CongressJosh GottheimerNJ-NJ05Purchasesince trade -18.8%, vs market -185.2%$1K–$15K

More: congressional trades on BMRN · insider activity · executive branch · trending